Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, uppe… Read more
Marksans Pharma Limited (MARKSANS) - Total Liabilities
Latest total liabilities as of September 2025: ₹7.28 Billion INR
Based on the latest financial reports, Marksans Pharma Limited (MARKSANS) has total liabilities worth ₹7.28 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Marksans Pharma Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Marksans Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Marksans Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Marksans Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OSAKA Titanium technologies Co.Ltd
F:S5M
|
Germany | €60.69 Billion |
|
Guangzhou Grandbuy Co Ltd
SHE:002187
|
China | CN¥3.06 Billion |
|
AB Ignitis grupe
IL:IGN
|
UK | €3.61 Billion |
|
Calavo Growers Inc
NASDAQ:CVGW
|
USA | $83.69 Million |
|
ANGELALIGN TECHNOLOGY INC
PINK:AGLFF
|
USA | $298.16 Million |
|
Shanghai SK Petroleum & Chemical Equipment Corp Ltd
SHE:002278
|
China | CN¥622.46 Million |
|
Mah Sing Group Bhd
KLSE:8583
|
Malaysia | RM3.59 Billion |
|
Cognyte Software Ltd
NASDAQ:CGNT
|
USA | $287.38 Million |
Liability Composition Analysis (2005–2025)
This chart breaks down Marksans Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.47 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marksans Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marksans Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Marksans Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹7.50 Billion | +26.08% |
| 2024-03-31 | ₹5.95 Billion | +39.91% |
| 2023-03-31 | ₹4.25 Billion | +1.96% |
| 2022-03-31 | ₹4.17 Billion | +29.18% |
| 2021-03-31 | ₹3.23 Billion | +30.35% |
| 2020-03-31 | ₹2.48 Billion | -1.31% |
| 2019-03-31 | ₹2.51 Billion | +0.92% |
| 2018-03-31 | ₹2.49 Billion | -17.48% |
| 2017-03-31 | ₹3.01 Billion | +16.19% |
| 2016-03-31 | ₹2.59 Billion | -9.82% |
| 2015-03-31 | ₹2.88 Billion | -15.70% |
| 2014-03-31 | ₹3.41 Billion | +10.89% |
| 2013-03-31 | ₹3.08 Billion | -44.12% |
| 2012-03-31 | ₹5.51 Billion | +2.23% |
| 2011-03-31 | ₹5.39 Billion | +11.42% |
| 2010-03-31 | ₹4.84 Billion | +1.03% |
| 2009-03-31 | ₹4.79 Billion | +16.98% |
| 2008-03-31 | ₹4.09 Billion | +12.41% |
| 2007-03-31 | ₹3.64 Billion | +4.82% |
| 2006-03-31 | ₹3.47 Billion | +161.74% |
| 2005-03-31 | ₹1.33 Billion | -- |